"It gets people through the door": a qualitative case study of the use of incentives in the care of people at risk or living with HIV in British Columbia, Canada.


Journal

BMC medical ethics
ISSN: 1472-6939
Titre abrégé: BMC Med Ethics
Pays: England
ID NLM: 101088680

Informations de publication

Date de publication:
27 10 2020
Historique:
received: 04 05 2020
accepted: 16 10 2020
entrez: 28 10 2020
pubmed: 29 10 2020
medline: 29 7 2021
Statut: epublish

Résumé

There has been growing interest in the use of incentives to increase the uptake of health-related behaviours and achieve desired health outcomes at the individual and population level. However, the use of incentives remains controversial for ethical reasons. An area in which incentives have been not only proposed but used is HIV prevention, testing, treatment and care-each one representing an interconnecting step in the "HIV Cascade." The main objective of this qualitative case study was to document the experiences of health care and service providers tasked with administrating incentivized HIV testing, treatment, and care in British Columbia, Canada. A second objective was to explore the ethical and professional tensions that arise from the use of incentives as well as strategies used by providers to mitigate them. We conducted interviews with 25 providers and 6 key informants, which were analyzed using applied thematic analysis. We also collected documents and took field notes. Our findings suggest that incentives target populations believed to pose the most risk to public health. As such, incentives are primarily used to close the gaps in the HIV Cascade by getting the "right populations" to test, start treatment, stay on treatment, and, most importantly, achieve (and sustain) viral suppression. Participants considered that incentives work because they "bring people through the door." However, they believed the effectiveness of incentives to be superficial, short-lived and one-dimensional-thus, failing to address underlying structural barriers to care and structural determinants of health. They also raised concerns about the unintended consequences of incentives and the strains they may put on the therapeutic relationship. They had developed strategies to mitigate the ensuing ethical and professional tensions and to make their work feel relational rather than transactional. We identify an urgent need to problematize the use of incentives as a part of the "HIV Cascade" agenda and interrogate the ethics of engaging in this practice from the perspective of health care and service providers. More broadly, we question the introduction of market logic into the realm of health care-an area of life previously not subject to monetary exchanges.

Sections du résumé

BACKGROUND
There has been growing interest in the use of incentives to increase the uptake of health-related behaviours and achieve desired health outcomes at the individual and population level. However, the use of incentives remains controversial for ethical reasons. An area in which incentives have been not only proposed but used is HIV prevention, testing, treatment and care-each one representing an interconnecting step in the "HIV Cascade."
METHODS
The main objective of this qualitative case study was to document the experiences of health care and service providers tasked with administrating incentivized HIV testing, treatment, and care in British Columbia, Canada. A second objective was to explore the ethical and professional tensions that arise from the use of incentives as well as strategies used by providers to mitigate them. We conducted interviews with 25 providers and 6 key informants, which were analyzed using applied thematic analysis. We also collected documents and took field notes.
RESULTS
Our findings suggest that incentives target populations believed to pose the most risk to public health. As such, incentives are primarily used to close the gaps in the HIV Cascade by getting the "right populations" to test, start treatment, stay on treatment, and, most importantly, achieve (and sustain) viral suppression. Participants considered that incentives work because they "bring people through the door." However, they believed the effectiveness of incentives to be superficial, short-lived and one-dimensional-thus, failing to address underlying structural barriers to care and structural determinants of health. They also raised concerns about the unintended consequences of incentives and the strains they may put on the therapeutic relationship. They had developed strategies to mitigate the ensuing ethical and professional tensions and to make their work feel relational rather than transactional.
CONCLUSIONS
We identify an urgent need to problematize the use of incentives as a part of the "HIV Cascade" agenda and interrogate the ethics of engaging in this practice from the perspective of health care and service providers. More broadly, we question the introduction of market logic into the realm of health care-an area of life previously not subject to monetary exchanges.

Identifiants

pubmed: 33109165
doi: 10.1186/s12910-020-00548-5
pii: 10.1186/s12910-020-00548-5
pmc: PMC7590593
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105

Subventions

Organisme : CIHR
ID : 159826
Pays : Canada

Références

Health Psychol Rev. 2014;8(3):286-95
pubmed: 25053215
J Int AIDS Soc. 2013 Aug 23;16:18615
pubmed: 23972159
J Health Polit Policy Law. 2012 Apr;37(2):201-26
pubmed: 22147947
Circ Cardiovasc Qual Outcomes. 2009 Sep;2(5):514-6
pubmed: 20031885
Int J Behav Med. 2014 Dec;21(6):995-1004
pubmed: 24281939
Prev Med. 2015 Apr;73:145-58
pubmed: 25600881
Prev Med. 2012 Nov;55 Suppl:S86-94
pubmed: 22580095
Afr J AIDS Res. 2014;13(2):153-60
pubmed: 25174632
Am J Prev Med. 2013 Nov;45(5):658-67
pubmed: 24139781
PLoS Med. 2017 Nov 21;14(11):e1002443
pubmed: 29161265
Glob Public Health. 2020 Mar;15(3):321-333
pubmed: 31596684
Am J Prev Med. 2013 Jun;44(6):659-65
pubmed: 23683984
Health Expect. 2011 Jun;14(2):191-200
pubmed: 21348904
J Clin Psychopharmacol. 2015 Apr;35(2):120-7
pubmed: 25692797
Am J Bioeth. 2012;12(2):1-10
pubmed: 22304506
BMJ. 2012 Aug 13;345:e5047
pubmed: 22893568
AIDS Behav. 2019 Sep;23(9):2443-2452
pubmed: 31098747
J Assoc Nurses AIDS Care. 2017 Sep - Oct;28(5):770-783
pubmed: 28629800
Curr HIV/AIDS Rep. 2012 Dec;9(4):364-74
pubmed: 22968432
Behav Med. 2017 Apr-Jun;43(2):79-90
pubmed: 26431076
AIDS Behav. 2014 May;18(5):905-12
pubmed: 24068389
Curr HIV/AIDS Rep. 2019 Aug;16(4):292-303
pubmed: 31201613
HIV Res Clin Pract. 2020 Feb;21(1):1-10
pubmed: 32133931
J Subst Abuse Treat. 2017 Jan;72:10-18
pubmed: 27746057
N Engl J Med. 2010 Jan 14;362(2):e3
pubmed: 20042747
AIDS Care. 2018;30(sup3):85-98
pubmed: 29985055
Afr J AIDS Res. 2016;15(1):17-25
pubmed: 27002355
Am J Health Promot. 2015 May-Jun;29(5):314-23
pubmed: 25928816
Can J Diabetes. 2015 Feb;39(1):83-7
pubmed: 25444683
Pediatrics. 2015 Mar;135(3):e687-702
pubmed: 25647672
Prev Med. 2015 Jun;75:75-85
pubmed: 25843244
J Nurs Manag. 2011 Apr;19(3):293-301
pubmed: 21507099
AIDS Behav. 2014 Oct;18 Suppl 5:S505-15
pubmed: 23842717
Lancet Infect Dis. 2016 Nov;16(11):1215-1216
pubmed: 27788971
Curr Opin HIV AIDS. 2015 Nov;10(6):451-63
pubmed: 26371461
J Med Ethics. 2017 Mar;43(3):140-144
pubmed: 27738254
J Acquir Immune Defic Syndr. 2019 Dec;82 Suppl 3:S183-S191
pubmed: 31764253
PLoS One. 2014 Mar 11;9(3):e90347
pubmed: 24618584
Int J Behav Med. 2013 Mar;20(1):114-20
pubmed: 22094998
J Med Philos. 2008 Jun;33(3):198-220
pubmed: 18567903
J Med Ethics. 2017 Mar;43(3):150-156
pubmed: 27738256
Ann Behav Med. 2012 Dec;44(3):375-88
pubmed: 22907712
Pediatrics. 2014 Oct;134(4):e1117-28
pubmed: 25225138
Can J Psychiatry. 2014 Jul;59(7):385-92
pubmed: 25007422
J Community Health. 2014 Dec;39(6):1133-9
pubmed: 24705680
Prev Med. 2019 Sep;126:105762
pubmed: 31271816
Qual Health Res. 2013 Sep;23(9):1267-75
pubmed: 23925405
Hastings Cent Rep. 1975 Feb;5(1):17-24
pubmed: 1093999
Health Risk Soc. 2019 Jan 31;21(1-2):1-16
pubmed: 31105468
Med Care Res Rev. 2008 Dec;65(6 Suppl):36S-78S
pubmed: 19015378
JAMA. 2016 Jul 12;316(2):156-70
pubmed: 27404184
J Acad Nutr Diet. 2014 Jul;114(7):1023-35
pubmed: 24836967
Nurs Inq. 2010 Dec;17(4):336-45
pubmed: 21059151
PLoS One. 2020 Jan 15;15(1):e0227623
pubmed: 31940422
J Med Ethics. 2017 Mar;43(3):162-166
pubmed: 27354248
AIDS Behav. 2012 Oct;16(7):1729-38
pubmed: 22760738
Cochrane Database Syst Rev. 2019 Jul 17;7:CD004307
pubmed: 31313293
JAMA Intern Med. 2017 Aug 1;177(8):1083-1092
pubmed: 28628702
AIDS Behav. 2019 Sep;23(9):2337-2346
pubmed: 31297681
JAMA. 2019 Apr 16;321(15):1451-1452
pubmed: 30907936
Int J Behav Med. 2014 Feb;21(1):202-5
pubmed: 23813122

Auteurs

Marilou Gagnon (M)

Canadian Institute for Substance Use Research, University of Victoria, 2300 McKenzie Ave, Victoria, BC, V8N 5M8, Canada. marilougagnon@uvic.ca.

Adrian Guta (A)

School of Social Work, University of Windsor, 167 Ferry Street, Windsor, ON, N9A 0C5, Canada.

Ross Upshur (R)

Dalla Lana Chair in Clinical Public Health, Dalla Lana School of Public Health, 678-155 College Street, Toronto, ON, M5T 3M7, Canada.

Stuart J Murray (SJ)

Canada Research Chair in Rhetoric and Ethics, Department of English Language and Literature, Carleton University, 1125 Colonel By Drive, Ottawa, ON, K1S 5B6, Canada.

Vicky Bungay (V)

Canada Research Chair in Gender, Equity and Community Engagement, School of Nursing, University of British Columbia, T201-2211 Wesbrook Mall, Vancouver, BC, V6T2B5, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH